[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351862-105":59,"doc-detail-351862-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","il-10-secretion-by-cd8-t-cells-orchestrates-early-nk-cell-recruitment-and-antitumor-immunity-after-anti-vegfr-2pd-1-therapy","IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy","","Background: Combining antiangiogenic therapy with immune checkpoint blockade benefits multiple cancers, yet the early intratumoral immune mechanisms remain unclear. Methods: In preclinical colorectal cancer models, combined VEGFR-2 and PD-1 blockade was used to evaluate immune changes. Results: CD8 T cells rapidly respond to VEGFR-2 inhibition, expand intratumorally, and produce IL-10; this IL-10 recruits NK cells that activate effectors and induce GM-CSF, macrophage maturation, and CXCL11. This cascade amplifies secondary CD8 infiltration and sustains antitumor activity. Conclusions: CD8 T cell-derived IL-10 coordinates early innate–adaptive immunity required for therapeutic efficacy in two models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/il-10-secretion-by-cd8-t-cells-orchestrates-early-nk-cell-recruitment-and-antitumor-immunity-after-anti-vegfr-2pd-1-therapy/351862/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/il-10-secretion-by-cd8-t-cells-orchestrates-early-nk-cell-recruitment-and-antitumor-immunity-after-anti-vegfr-2pd-1-therapy/351862.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What immune events occur early after anti-VEGFR-2/PD-1 therapy?","Question",{"text":112,"@type":113},"CD8 T cells respond early to VEGFR-2 inhibition, expand in the tumor, and produce IL-10 shortly after treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CD8 T cell-derived IL-10 affect other immune cells?",{"text":117,"@type":113},"IL-10 promotes recruitment of NK cells into tumors, enabling NK-cell effector activity and subsequent GM-CSF production.",{"name":119,"@type":110,"acceptedAnswer":120},"What is required for the therapeutic benefit of the combined treatment?",{"text":121,"@type":113},"Disrupting IL-10 signaling or NK-cell function eliminates the benefit, while regulatory T-cell depletion further improves tumor control.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351862,1790718903,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":138,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":139,"faqs":140,"seo_title":141,"seo_description":67,"update_tm":142,"read_time":143,"preview_page_count":19,"preview_urls":144},4398046744996,"Open access Original research  \nIL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after antiVEGFR-2/PD-1 therapy  \nMannon Geindreau,1 Cassandre Pignol,1 Loïs Coënon,1 Alexis Varin,2  \nCindy Racoeur,1,3 Lylou Milian,1 Nolwenn Roger,1 Fanny Chalmin,4 Thibault Vernet,4 Line Alibert,1 Pierre-Simon Bellaye,1,5 Marion Thibaudin  ,4 Cynthia Louis,6 Ian Wicks,6 Caroline Truntzer  ,2 Romain Boidot,7 Catherine Paul  ,1,3 Baptiste Lamarthée,2 Frederique Vegran  ,4 Francois Ghiringhelli  ,4,8,9 Mélanie Bruchard  4  \nTo cite: Geindreau M, Pignol C, Coënon L, et al. IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after antiVEGFR-2/PD-1 therapy. Journal for ImmunoTherapy of Cancer 2026;14:e015243 . doi:10 . 1136/ jitc-2026-015243  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2026-015243](jitc-2026-015243)) .  \nMG and CP contributed equally. Accepted 30 May 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Mélanie Bruchard;  \n[melanie.bruchard@inserm.fr](melanie.bruchard@inserm.fr)  \nABSTRACT  \nBackground The combination of antiangiogenic therapy with immune checkpoint blockade has demonstrated significant clinical benefits in various cancers, however, the precise mechanisms of action on the immune system are not fully understood. In particular, the early intratumoral immune responses induced by angiogenesis inhibition remain unclear.  \nMethods Using preclinical models of colorectal cancer, we examined the immune changes elicited by combined vascular endothelial growth factor receptor-2 (VEGFR-2) and programmed cell death protein-1 (PD-1) blockade. Results Our findings reveal that CD8 T cells respond directly and early to VEGFR-2 inhibition, preceding the acquisition of overt cytotoxic function. Shortly after treatment, intratumoral CD8 T cells expanded and produced interleukin-10 (IL-10) . Unexpectedly, this CD8 T cell-derived IL-10 promoted the recruitment of natural killer (NK) cells into tumors. Recruited NK cells subsequently gained effector activity and produced granulocyte-macrophage colony-stimulating factor, which supported macrophage maturation and the induction of CXCL11 . This sequence of events enhanced secondary CD8 T-cell infiltration and sustained antitumor immune activity. Disruption of IL-10 signaling or NK-cell function eliminated the therapeutic benefit of combined VEGFR-2 and PD-1 blockade, whereas regulatory T-cell depletion further improved tumor control.  \nConclusions Together, these findings identify an unanticipated role for CD8 T cell-derived IL-10 in coordinating early innate and adaptive immune responses following angiogenesis inhibition and define an immune program initiated by VEGFR-2 blockade that is required for therapeutic efficacy in two preclinical colorectal cancer models.  \nINTRODUCTION  \nTumor angiogenesis is essential for tumor growth, therefore, targeting of the vascular endothelial growth factor (VEGF) and its receptor  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Combined antiangiogenic (vascular endothelial growth factor receptor-2/vascular endothelial growth factor) therapy and programmed cell death protein-1 immune checkpoint blockade improve clinical outcomes in several cancers, but the early immune mechanisms driving their efficacy remain poorly understood.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study identifies an unexpected early immune cascade in which CD8 T cell–derived interleukin-10 (IL-10) recruits natural killer (NK) cells, leading to granulocyte-macrophage colony-stimulating factormediated macrophage activation and subsequent CXCL11-driven amplification of antitumor CD8 Tcell res","cbCailjNtCxfw5DD","https://ap.wps.com/l/cbCailjNtCxfw5DD","pdf",5625571,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Tumor angiogenesis and VEGF signaling","[{\"question\":\"What immune events occur early after anti-VEGFR-2/PD-1 therapy?\",\"answer\":\"CD8 T cells respond early to VEGFR-2 inhibition, expand in the tumor, and produce IL-10 shortly after treatment.\"},{\"question\":\"How does CD8 T cell-derived IL-10 affect other immune cells?\",\"answer\":\"IL-10 promotes recruitment of NK cells into tumors, enabling NK-cell effector activity and subsequent GM-CSF production.\"},{\"question\":\"What is required for the therapeutic benefit of the combined treatment?\",\"answer\":\"Disrupting IL-10 signaling or NK-cell function eliminates the benefit, while regulatory T-cell depletion further improves tumor control.\"}]","IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy | PDF",1790096352,48,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/870da4b88a33216e6ec32a2a03a711c7.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d8f9c9376116d4403a68ceb4e1b0e95.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81a227ad7c8b21615ee0866336dbaffb.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37260ceedfa0bdbaad566d7d79c4e6ed.webp",980,1306]